Table 1 Characteristics of included studies
Author | Country of study | Period of sampling | Year of publication | Study design | Sample size | Prevalence assessed | |
|---|---|---|---|---|---|---|---|
MDR | ESBL | ||||||
[20] | Malaysia | September-December 2014 | 2020 | – | 97 | Y | Y |
[13] | Thailand | December 2004–May 2005 | 2008 | – | 1001 | N | Y |
[8] | Vietnam | February–September 2015 | 2019 | Prevalence Survey | 57 | Y | Y |
[3] | Malaysia | 2010–2012 | 2015 | Investigation/Survey | 93 | N | Y |
[39] | Singapore | 1st May 2014–30th April 2016 | 2019 | - | 140 | N | Y |
[38] | Indonesia | 2015 | 2021 | Investigation/Survey | 94 | N | Y |
[37] | Cambodia | 2012 | 2019 | Prevalence study | 196 | N | Y |
[27] | Thailand | April 2004-August 2005 | 2008 | Investigation/Survey | 31 | N | Y |
[29] | Indonesia | April until October 2013 & April until August 2014 | 2020 | Prospective observational | 200 | Y | N |
[4] | Thailand | January 1 through 30, 2006 | 2008 | – | 71 | N | Y |
[36] | Vietnam | March and June 2010 | 2013 | – | 72 | N | Y |
[16] | Malaysia | 1st June–31st August 2017 | 2021 | Prospective cohort | 139 | Y | Y |
[5] | Myanmar | January 2018 | 2021 | Prevalence | 191 | N | Y |
[35] | Philippines | August–November 2017 | 2018 | Prevalence | 32 | Y | Y |
[15] | Thailand | August 2000-January 2001 | 2004 | Prospective study | 400 | N | Y |
[22] | Malaysia | 2009 and 2012 | 2016 | Cross-sectional Descriptive study | 141 | N | Y |
[31] | Indonesia | – | 2019 | Prospective cohort | 72 | N | Y |
[17] | Malaysia | 2004 | 2009 | – | 51 | Y | Y |
[30] | Indonesia | January–April 2005 | 2010 | Investigation/Survey | 291 | N | Y |
[14] | Thailand | July 1, 2004, through June 30, 2005 | 2007 | – | 320 | N | Y |
[18] | Malaysia | 2013 | 2017 | Investigation/Survey | 17 | Y | Y |